SARS-CoV-2 isolation from the first reported patients in Brazil and establishment of a coordinated task network

Autor(es):Mostrar menos -

Danielle Bastos Araujo ; Rafael Rahal Guaragna Machado ^[2] ; Deyvid Emanuel Amgarten ^[3] ; Fernanda de Mello Malta ^[4] ; Gabriel Guarany de Araujo ^[5] ; Cairo Oliveira Monteiro ^[6] ; Erika Donizetti Candido ^[7] ; Camila Pereira Soares ^[8] ; Fernando Gatti de Menezes ^[9] ; Ana Carolina Cornachioni Pires ^[10] ; Rúbia Anita Ferraz Santana ^[11] ; Amanda de Oliveira Viana ^[12] ; Erick Dorlass ^[13] ; Luciano Thomazelli ^[14] ; Luis Carlos de Sousa Ferreira ^[15] ; Viviane Fongaro Botosso ^[16] ; Cristiane Rodrigues Guzzo Carvalho ^[17] ; Danielle Bruna Leal Oliveira ; João Renato Rebello Pinho ; Edison Luiz Durigon

• Tipo de documento: Artigo Científico
• Fonte: Memórias do Instituto Oswaldo Cruz; v. 115, 2020-10-23.

Resumo

BACKGROUND Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was confirmed in Brazil in February 2020, the first cases were followed by an increase in the number of cases throughout the country, resulting in an important public health crisis that requires fast and coordinated responses. OBJECTIVES The objective of this work is to describe the isolation and propagation properties of SARS-CoV-2 isolates from the first confirmed cases of coronavirus disease 2019 (COVID-19) in Brazil. METHODS After diagnosis in patients that returned from Italy to the São Paulo city in late February by RT-PCR, SARS-CoV-2 isolates were obtained in cell cultures and characterised by full genome sequencing, electron microscopy and in vitro replication properties. FINDINGS The virus isolate was recovered from nasopharyngeal specimen, propagated in Vero cells (E6, CCL-81 and hSLAM), with clear cytopathic effects, and characterised by full genome sequencing, electron microscopy and in vitro replication properties. Virus stocks - viable (titre 2.11 × 106 TCID50/mL, titre 1.5 × 106 PFUs/mL) and inactivated from isolate SARS.CoV2/SP02.2020.HIAE.Br were prepared and set available to the public health authorities and the scientific community in Brazil and abroad. MAIN CONCLUSION We believe that the protocols for virus growth and studies here described and the distribution initiative may constitute a viable model for other developing countries, not only to help a rapid effective pandemic response, but also to facilitate and support basic scientific research. (AU)

• Processo FAPESP: 18/21076-9 - Estrutura da secretina do pilus tipo IV de Xanthomonas citri
• Beneficiário: Gabriel Guarany de Araujo
• Modalidade de apoio: Bolsas no Brasil - Doutorado
• Processo FAPESP: 17/24769-2 - Zika vírus em puérperas e neonatos: soroepidemiologia e caracterização molecular
• Beneficiário: Rafael Rahal Guaragna Machado
• Modalidade de apoio: Bolsas no Brasil - Doutorado Direto
• Processo FAPESP: 20/06409-1 - Avaliação da resposta imune humoral e da resposta inflamatória em pacientes com diagnóstico confirmado de COVID-19 no Hospital Sírio Libanês e correlação com a severidade da doença
• Beneficiário: Edison Luiz Durigon
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 16/20045-7 - Descoberta de antígenos e desenvolvimento de métodos de diagnóstico sorológico e estratégias vacinais contra o Vírus Zika (ZIKV)
• Beneficiário: Luis Carlos de Souza Ferreira
• Modalidade de apoio: Auxílio à Pesquisa - Temático
• Processo FAPESP: 17/25123-9 - Monitoramento de ectoparasitas e vírus em morcegos em resíduo urbano de Mata Atlântica
• Beneficiário: Amanda de Oliveira Viana
• Modalidade de apoio: Bolsas no Brasil - Mestrado
• Processo FAPESP: 18/23680-0 - Padronização da técnica Sherlock (Specific High-Sensitivity Enzymatic Reporter Unlocking) utilizando a proteína Cas13a para diagnóstico do vírus respiratório sincicial em pacientes pediátricos
• Beneficiário: Camila Pereira Soares
• Modalidade de apoio: Bolsas no Brasil - Mestrado
• Processo FAPESP: 20/04680-0 - Desenho de diferentes fragmentos da proteína de superfície, spike, do SARS-CoV-2, para desenvolvimento de testes rápidos e de vacina
• Beneficiário: Cristiane Rodrigues Guzzo Carvalho
• Modalidade de apoio: Auxílio à Pesquisa - Regular